NewAmsterdam Pharma (NAMS) Stock Forecast, Price Target & Predictions
NAMS Stock Forecast
NewAmsterdam Pharma stock forecast is as follows: an average price target of $41.50 (represents a 99.71% upside from NAMS’s last price of $20.78) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
NAMS Price Target
The average price target for NewAmsterdam Pharma (NAMS) is $41.50 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $48.00 to $36.00. This represents a potential 99.71% upside from NAMS's last price of $20.78.
NAMS Analyst Ratings
According to 6 Wall Street analysts, NewAmsterdam Pharma's rating consensus is 'Buy'. The analyst rating breakdown for NAMS stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
NewAmsterdam Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 30, 2024 | Ed Arce | H.C. Wainwright | $48.00 | $25.60 | 87.50% | 130.99% |
| Nov 20, 2024 | Roanna Ruiz | Leerink Partners | $45.00 | $20.01 | 124.89% | 116.55% |
| Sep 23, 2024 | Yasmeen Rahimi | Piper Sandler | $37.00 | $15.95 | 131.97% | 78.06% |
| Aug 28, 2024 | Serge Belanger | Needham | $36.00 | $16.77 | 114.67% | 73.24% |
The latest NewAmsterdam Pharma stock forecast, released on Dec 30, 2024 by Ed Arce from H.C. Wainwright, set a price target of $48.00, which represents a 87.50% increase from the stock price at the time of the forecast ($25.60), and a 130.99% increase from NAMS last price ($20.78).
NewAmsterdam Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 4 |
| Avg Price Target | $48.00 | $46.50 | $41.50 |
| Last Closing Price | $20.78 | $20.78 | $20.78 |
| Upside/Downside | 130.99% | 123.77% | 99.71% |
In the current month, the average price target of NewAmsterdam Pharma stock is $48.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 130.99% increase as opposed to NewAmsterdam Pharma's last price of $20.78. This month's average price target is up 3.23% compared to last quarter, and up 15.66% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 30, 2024 | H.C. Wainwright | Buy | Initialise | |
| Dec 11, 2024 | Jefferies | Buy | Buy | Hold |
| Nov 20, 2024 | Leerink Partners | Outperform | Outperform | Hold |
| Oct 21, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 23, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Sep 23, 2024 | RBC Capital | Buy | Buy | Hold |
| Sep 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 28, 2024 | Needham | Buy | Mixed | Initialise |
| Aug 28, 2024 | Needham | Buy | Initialise | |
| Aug 27, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 15, 2024 | Cowen & Co. | Buy | Initialise |
NewAmsterdam Pharma's last stock rating was published by H.C. Wainwright on Dec 30, 2024. The company Initialise its NAMS rating from "null" to "Buy".
NewAmsterdam Pharma Financial Forecast
NewAmsterdam Pharma Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $1.26M | $900.85K | $540.50K | $270.25K | $633.33K | $633.33K | $616.67K | $3.10M | $1.76M | $1.87M | $1.21M | $1.62M | $2.89M |
| High Forecast | $2.37M | $1.70M | $1.02M | $508.53K | $1.19M | $1.19M | $1.16M | $5.83M | $3.14M | $1.89M | $1.25M | $1.66M | $3.12M |
| Low Forecast | $149.17K | $106.55K | $63.93K | $31.96K | $74.91K | $74.91K | $72.94K | $366.67K | $1.06M | $1.85M | $1.16M | $1.57M | $2.65M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 1 | 1 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
NewAmsterdam Pharma's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NAMS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
NewAmsterdam Pharma EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 1 | 1 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $304.39K | $217.43K | $130.46K | $65.23K | $152.86K | $152.86K | $148.84K | $748.22K | $423.74K | $451.84K | $291.09K | $390.74K | $696.73K |
| High Forecast | $572.78K | $409.14K | $245.48K | $122.74K | $287.64K | $287.64K | $280.07K | $1.41M | $757.60K | $457.02K | $301.02K | $401.43K | $752.03K |
| Low Forecast | $36.00K | $25.72K | $15.43K | $7.71K | $18.08K | $18.08K | $17.60K | $88.50K | $256.81K | $446.65K | $281.16K | $380.05K | $639.22K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict NAMS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than NewAmsterdam Pharma's previous annual EBITDA (undefined) of $NaN.
NewAmsterdam Pharma Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 1 | 1 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-43.94M | $-41.60M | $-39.39M | $-38.68M | $-43.14M | $-42.29M | $-41.81M | $-52.82M | $-44.15M | $-42.35M | $-50.93M | $-54.48M | $-50.36M |
| High Forecast | $6.43M | $6.08M | $5.76M | $5.66M | $6.31M | $6.18M | $6.11M | $-25.15M | $-34.03M | $6.19M | $7.45M | $7.97M | $-46.02M |
| Low Forecast | $-94.30M | $-89.29M | $-84.54M | $-83.01M | $-92.59M | $-90.77M | $-89.74M | $-64.13M | $-48.75M | $-90.89M | $-109.31M | $-116.93M | $-58.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
NewAmsterdam Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NAMS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
NewAmsterdam Pharma SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 1 | 1 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $1.43M | $1.02M | $611.12K | $305.56K | $716.08K | $716.08K | $697.24K | $3.51M | $1.98M | $2.12M | $1.36M | $1.83M | $3.26M |
| High Forecast | $2.68M | $1.92M | $1.15M | $574.97K | $1.35M | $1.35M | $1.31M | $6.60M | $3.55M | $2.14M | $1.41M | $1.88M | $3.52M |
| Low Forecast | $168.66K | $120.47K | $72.28K | $36.14K | $84.70K | $84.70K | $82.47K | $414.57K | $1.20M | $2.09M | $1.32M | $1.78M | $2.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
NewAmsterdam Pharma's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NAMS last annual SG&A of $NaN (undefined).
NewAmsterdam Pharma EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 1 | 1 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.46 | $-0.44 | $-0.42 | $-0.41 | $-0.46 | $-0.45 | $-0.44 | $-0.56 | $-0.47 | $-0.45 | $-0.54 | $-0.57 | $-0.53 |
| High Forecast | $0.07 | $0.06 | $0.06 | $0.06 | $0.07 | $0.07 | $0.06 | $-0.27 | $-0.36 | $0.07 | $0.08 | $0.08 | $-0.49 |
| Low Forecast | $-1.00 | $-0.94 | $-0.89 | $-0.88 | $-0.98 | $-0.96 | $-0.95 | $-0.68 | $-0.51 | $-0.96 | $-1.15 | $-1.23 | $-0.61 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, NewAmsterdam Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NAMS previous annual EPS of $NaN (undefined).
NewAmsterdam Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PEPG | PepGen | $1.84 | $29.50 | 1503.26% | Buy |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.54 | $6.00 | 289.61% | Buy |
| PRTC | PureTech Health | $18.64 | $57.00 | 205.79% | Buy |
| CGEM | Cullinan Oncology | $11.25 | $34.00 | 202.22% | Buy |
| MLYS | Mineralys Therapeutics | $10.36 | $30.00 | 189.58% | Buy |
| NAMS | NewAmsterdam Pharma | $20.78 | $41.50 | 99.71% | Buy |
| MRUS | Merus | $41.65 | $81.25 | 95.08% | Buy |
| CRNX | Crinetics Pharmaceuticals | $39.38 | $69.00 | 75.22% | Buy |
| JANX | Janux Therapeutics | $42.51 | $70.25 | 65.26% | Buy |
| REPL | Replimune Group | $14.07 | $23.00 | 63.47% | Buy |
| CMPX | Compass Therapeutics | $3.11 | $5.00 | 60.77% | Buy |
| RZLT | Rezolute | $5.06 | $6.67 | 31.82% | Buy |